Shares of TransEnterix, Inc. (NYSEAMERICAN:TRXC) gapped up before the market opened on Monday . The stock had previously closed at $4.08, but opened at $3.79. TransEnterix shares last traded at $3.75, with a volume of 156015 shares traded.
A number of brokerages recently commented on TRXC. LADENBURG THALM/SH SH lowered TransEnterix from a “buy” rating to a “neutral” rating and increased their price target for the company from $3.50 to $4.00 in a research note on Tuesday, May 29th. Zacks Investment Research raised TransEnterix from a “strong sell” rating to a “hold” rating in a research note on Wednesday, May 9th. Finally, BTIG Research raised TransEnterix from a “neutral” rating to a “buy” rating in a research note on Wednesday, May 9th.
TransEnterix (NYSEAMERICAN:TRXC) last issued its quarterly earnings results on Tuesday, May 8th. The medical instruments supplier reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.01. TransEnterix had a negative return on equity of 137.69% and a negative net margin of 21,045.36%. The firm had revenue of $4.77 million for the quarter, compared to the consensus estimate of $3.81 million.
In other TransEnterix news, COO Anthony C. J. Fernando sold 27,000 shares of the firm’s stock in a transaction on Friday, June 1st. The stock was sold at an average price of $3.67, for a total transaction of $99,090.00. Following the transaction, the chief operating officer now directly owns 50,349 shares in the company, valued at approximately $184,780.83. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new stake in shares of TransEnterix in the 4th quarter worth $109,000. Raymond James Financial Services Advisors Inc. acquired a new stake in shares of TransEnterix in the 4th quarter worth $113,000. Barclays PLC acquired a new stake in shares of TransEnterix in the 1st quarter worth $164,000. Bank of New York Mellon Corp boosted its position in shares of TransEnterix by 94.0% in the 4th quarter. Bank of New York Mellon Corp now owns 119,584 shares of the medical instruments supplier’s stock worth $231,000 after purchasing an additional 57,944 shares in the last quarter. Finally, Iguana Healthcare Management LLC acquired a new stake in shares of TransEnterix in the 4th quarter worth $241,000.
TransEnterix Company Profile
TransEnterix, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe.
Receive News & Ratings for TransEnterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransEnterix and related companies with MarketBeat.com's FREE daily email newsletter.